A patient with HIV is newly diagnosed with multidrug-resistant tuberculosis. Which of the following is the appropriate regimen, and what should the patient be monitored for?

Explanation

## Correct Answer: A. BPaLM; monitor for immune reconstitution syndrome BPaLM (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) is the WHO-recommended first-line regimen for multidrug-resistant tuberculosis (MDR-TB) in HIV-coinfected patients, particularly those with low CD4 counts. This newer regimen has superior efficacy and faster bactericidal activity compared to older MDR-TB regimens, with cure rates exceeding 90% in clinical trials. The critical monitoring point is **immune reconstitution inflammatory syndrome (IRIS)**, which occurs when antiretroviral therapy (ART) is initiated alongside TB treatment in severely immunocompromised patients (CD4 <50 cells/µL). IRIS manifests as paradoxical worsening of TB symptoms or new TB lesions despite microbiological improvement, driven by restoration of Th1-mediated immunity. In Indian TB programs (NTEP guidelines), BPaLM is now preferred for MDR-TB/HIV coinfection due to shorter treatment duration (20 weeks) and better tolerability. The regimen avoids excessive hepatotoxicity and ototoxicity seen with older regimens, making it safer in resource-limited settings where monitoring capacity may be limited. ## Why the other options are wrong **B. INH + Levofloxacin + Streptomycin + Ethionamide, monitor for pyridoxine deficiency** — This is an outdated MDR-TB regimen that does not meet current WHO/NTEP standards for HIV-coinfected patients. While pyridoxine deficiency is a real concern with INH and ethionamide, this regimen lacks bedaquiline and pretomanid—the backbone of modern MDR-TB therapy. Streptomycin is also contraindicated in advanced HIV due to ototoxicity risk. The regimen is suboptimal for TB/HIV coinfection. **C. INH + Clarithromycin + Pyrazinamide + Ethambutol, monitor for optic neuritis** — This is a regimen for drug-susceptible TB or MAC prophylaxis, not MDR-TB. Clarithromycin is used for MAC prophylaxis in HIV (CD4 <50), not TB treatment. This combination lacks fluoroquinolones and second-line drugs essential for MDR-TB. Optic neuritis is a real ethambutol toxicity, but the regimen itself is fundamentally incorrect for MDR-TB diagnosis. **D. INH + Levofloxacin + Pyrazinamide + Ethambutol, monitor for hepatotoxicity** — This regimen omits bedaquiline and pretomanid, which are mandatory for MDR-TB. It appears to be a drug-susceptible TB regimen with a fluoroquinolone add-on, not a true MDR-TB regimen. While hepatotoxicity is a valid concern with INH and pyrazinamide, this regimen lacks the potency and bactericidal activity required for MDR-TB/HIV coinfection and would result in treatment failure. ## High-Yield Facts - **BPaLM regimen** (Bedaquiline 200 mg daily, Pretomanid 200 mg daily, Linezolid 600 mg daily, Moxifloxacin 400 mg daily) is WHO-recommended first-line for MDR-TB in HIV with cure rates >90%. - **Immune reconstitution inflammatory syndrome (IRIS)** occurs 2–12 weeks after ART initiation in TB/HIV coinfection with CD4 <50, presenting as paradoxical TB worsening despite microbiological improvement. - **NTEP guidelines** (India's National TB Elimination Program) now recommend BPaLM for MDR-TB/HIV with 20-week treatment duration, replacing older regimens with streptomycin and ethionamide. - **Linezolid toxicity** (peripheral neuropathy, optic neuritis, bone marrow suppression) requires monitoring, especially in prolonged use; dose adjustment may be needed in advanced HIV. - **Bedaquiline** is a mycobacterial ATP synthase inhibitor with bactericidal activity; QT prolongation risk requires baseline ECG and monitoring, particularly with fluoroquinolones. ## Mnemonics **BPaLM = Modern MDR-TB** **B**edaquiline + **P**retomanid + **L**inezolid + **M**oxifloxacin. Remember: Bedaquiline (ATP synthase inhibitor) + Pretomanid (nitroimidazole) = synergistic bactericidal activity. Use when you see MDR-TB + HIV together. **IRIS Trigger in TB/HIV** **I**mmune **R**econstitution **I**nflammatory **S**yndrome = CD4 <50 + ART started + TB treatment ongoing = paradoxical worsening. Think: immune system 'wakes up' and overreacts to TB antigens. ## NBE Trap NBE pairs older MDR-TB regimens (with streptomycin, ethionamide, or clarithromycin) with plausible toxicities (pyridoxine deficiency, optic neuritis, hepatotoxicity) to trap students who memorize side effects without knowing current WHO/NTEP guidelines for TB/HIV coinfection. The correct answer requires knowledge of the newer BPaLM regimen and IRIS as the specific monitoring concern. ## Clinical Pearl In Indian TB programs, a newly diagnosed MDR-TB/HIV patient with CD4 <50 cells/µL requires BPaLM + ART initiation within 2 weeks of TB diagnosis. The clinician must counsel the patient that TB symptoms may paradoxically worsen in the first 4–8 weeks (IRIS) despite microbiological cure—this is expected and does not indicate treatment failure. Close CD4 monitoring and corticosteroid use (prednisone 1 mg/kg) may be needed if IRIS is severe. _Reference: NTEP Guidelines (India) 2023; WHO TB/HIV Guidelines 2023; KD Tripathi Pharmacology Ch. 47 (Antituberculous drugs)_